Skip to content
10-Q

Quarterly Report

AVANIR PHARMACEUTICALS, INC.

0001193125-14-038532

← back to feed
Filed
Feb 6, 2014 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2014 · Jan 31, 2014 152.3M sh
Capex Q1 2014 · Dec 31, 2013 $1.26M
Capex Q1 2014 · Dec 31, 2012 $179.66K
Operating Cash Flow Q1 2014 · Dec 31, 2013 −$9.78M
Operating Cash Flow Q1 2014 · Dec 31, 2012 −$12.68M
Cash And Equivalents Q1 2014 · Dec 31, 2013 $43.9M
Cash And Equivalents Q1 2014 · Sep 30, 2013 $55.26M
Cash And Equivalents Q1 2014 · Dec 31, 2012 $56.94M
Cash And Equivalents Q1 2014 · Sep 30, 2012 $69.78M
Stockholders Equity Q1 2014 · Dec 31, 2013 $8.94M
Stockholders Equity Q1 2014 · Sep 30, 2013 $18.47M
Current Liabilities Q1 2014 · Dec 31, 2013 $32.12M
Current Liabilities Q1 2014 · Sep 30, 2013 $34.79M
Total Liabilities Q1 2014 · Dec 31, 2013 $52.33M
Total Liabilities Q1 2014 · Sep 30, 2013 $57.61M
Current Assets Q1 2014 · Dec 31, 2013 $56.11M
Current Assets Q1 2014 · Sep 30, 2013 $71.84M
Total Assets Q1 2014 · Dec 31, 2013 $61.27M
Total Assets Q1 2014 · Sep 30, 2013 $76.08M
Rd Expense Q1 2014 · Dec 31, 2013 $9.53M
Rd Expense Q1 2014 · Dec 31, 2012 $6.65M
Net Income Q1 2014 · Dec 31, 2013 −$10.95M
Net Income Q1 2014 · Dec 31, 2012 −$12.08M
Operating Income Q1 2014 · Dec 31, 2013 −$10M
Operating Income Q1 2014 · Dec 31, 2012 −$11.04M
Cost Of Revenue Q1 2014 · Dec 31, 2013 $1.29M
Cost Of Revenue Q1 2014 · Dec 31, 2012 $838.13K
Revenue Q1 2014 · Dec 31, 2013 $26.75M
Revenue Q1 2014 · Dec 31, 2012 $16.52M